Information Provided By:
Fly News Breaks for November 27, 2019
NVTA
Nov 27, 2019 | 07:46 EDT
Oppenheimer analyst Kevin DeGeeter, after speaking with management, continues to expect Invitae to provide Q4 revenue and 2020 guidance in mid-January. He believes 2020 offers Invitae "multiple avenues" for a growth rate "significantly above nearly all other publicly traded diagnostic companies." However, there is limited visibility on the pace of adoption curve or rate of market expansion, DeGeeter tells investors in a research note. As such, the analyst believes that if management provides 2020 guidance based on growth drivers with clearly established markets, which is their traditional approach, his $364.9M 2020 revenue estimate has downside risk. The analyst is above the consensus at $333.5M. DeGeeter keeps an Outperform rating on Invitae with a $34 price target. He believes such "conservative" guidance would have "paths to material upside."
News For NVTA From the Last 2 Days
NVTA
Jan 21, 2021 | 20:42 EST
The deal priced below the last closing price of $53.13. JPMorgan, Morgan Stanley, Cowen and SVB Leerink are acting as joint book running managers for the offering.
NVTA
Jan 20, 2021 | 18:32 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
NVTA
Jan 20, 2021 | 16:07 EST
J.P. Morgan Securities LLC, Morgan Stanley, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the proposed offering.